A randomized study of the efficacy and safety of intravenous acetaminophen vs. Intravenous placebo for the treatment of fever

Daniel H Kett, J. B. Breitmeyer, R. Ang, M. A. Royal

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This randomized, double-blind, placebo-controlled study evaluated the antipyretic effect and safety of intravenous (i.v.) acetaminophen using an endotoxin-induced fever model. Subjects exhibiting sufficient fever response following administration of reference standard endotoxin (RSE) were randomly assigned to receive i.v. acetaminophen 1,000mg (n = 31) or matching placebo (n = 29). The primary efficacy end point was the weighted sum of temperature differences from baseline through 6h. Relative to placebo, i.v. acetaminophen administration produced a rapid decrease in temperature that persisted throughout the 6-h study period. The primary end point favored i.v. acetaminophen over placebo (P 0.001). Temperature differences from baseline reached statistical significance at T30min after endotoxin administration (15min after completing the study medication infusion). Acetaminophen administered i.v. was well tolerated, and the frequency of adverse events was comparable to that after administration of i.v. placebo. This study shows that i.v. acetaminophen in a single 1,000-mg dose is safe and effective in reducing fever.

Original languageEnglish
Pages (from-to)32-39
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume90
Issue number1
DOIs
StatePublished - Jul 1 2011

Fingerprint

Acetaminophen
Fever
Placebos
Safety
Endotoxins
Intravenous Administration
Temperature
Therapeutics
Antipyretics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A randomized study of the efficacy and safety of intravenous acetaminophen vs. Intravenous placebo for the treatment of fever. / Kett, Daniel H; Breitmeyer, J. B.; Ang, R.; Royal, M. A.

In: Clinical Pharmacology and Therapeutics, Vol. 90, No. 1, 01.07.2011, p. 32-39.

Research output: Contribution to journalArticle

@article{ce8dae3c80774100933f4e028b815980,
title = "A randomized study of the efficacy and safety of intravenous acetaminophen vs. Intravenous placebo for the treatment of fever",
abstract = "This randomized, double-blind, placebo-controlled study evaluated the antipyretic effect and safety of intravenous (i.v.) acetaminophen using an endotoxin-induced fever model. Subjects exhibiting sufficient fever response following administration of reference standard endotoxin (RSE) were randomly assigned to receive i.v. acetaminophen 1,000mg (n = 31) or matching placebo (n = 29). The primary efficacy end point was the weighted sum of temperature differences from baseline through 6h. Relative to placebo, i.v. acetaminophen administration produced a rapid decrease in temperature that persisted throughout the 6-h study period. The primary end point favored i.v. acetaminophen over placebo (P 0.001). Temperature differences from baseline reached statistical significance at T30min after endotoxin administration (15min after completing the study medication infusion). Acetaminophen administered i.v. was well tolerated, and the frequency of adverse events was comparable to that after administration of i.v. placebo. This study shows that i.v. acetaminophen in a single 1,000-mg dose is safe and effective in reducing fever.",
author = "Kett, {Daniel H} and Breitmeyer, {J. B.} and R. Ang and Royal, {M. A.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1038/clpt.2011.98",
language = "English",
volume = "90",
pages = "32--39",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A randomized study of the efficacy and safety of intravenous acetaminophen vs. Intravenous placebo for the treatment of fever

AU - Kett, Daniel H

AU - Breitmeyer, J. B.

AU - Ang, R.

AU - Royal, M. A.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - This randomized, double-blind, placebo-controlled study evaluated the antipyretic effect and safety of intravenous (i.v.) acetaminophen using an endotoxin-induced fever model. Subjects exhibiting sufficient fever response following administration of reference standard endotoxin (RSE) were randomly assigned to receive i.v. acetaminophen 1,000mg (n = 31) or matching placebo (n = 29). The primary efficacy end point was the weighted sum of temperature differences from baseline through 6h. Relative to placebo, i.v. acetaminophen administration produced a rapid decrease in temperature that persisted throughout the 6-h study period. The primary end point favored i.v. acetaminophen over placebo (P 0.001). Temperature differences from baseline reached statistical significance at T30min after endotoxin administration (15min after completing the study medication infusion). Acetaminophen administered i.v. was well tolerated, and the frequency of adverse events was comparable to that after administration of i.v. placebo. This study shows that i.v. acetaminophen in a single 1,000-mg dose is safe and effective in reducing fever.

AB - This randomized, double-blind, placebo-controlled study evaluated the antipyretic effect and safety of intravenous (i.v.) acetaminophen using an endotoxin-induced fever model. Subjects exhibiting sufficient fever response following administration of reference standard endotoxin (RSE) were randomly assigned to receive i.v. acetaminophen 1,000mg (n = 31) or matching placebo (n = 29). The primary efficacy end point was the weighted sum of temperature differences from baseline through 6h. Relative to placebo, i.v. acetaminophen administration produced a rapid decrease in temperature that persisted throughout the 6-h study period. The primary end point favored i.v. acetaminophen over placebo (P 0.001). Temperature differences from baseline reached statistical significance at T30min after endotoxin administration (15min after completing the study medication infusion). Acetaminophen administered i.v. was well tolerated, and the frequency of adverse events was comparable to that after administration of i.v. placebo. This study shows that i.v. acetaminophen in a single 1,000-mg dose is safe and effective in reducing fever.

UR - http://www.scopus.com/inward/record.url?scp=79959373438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959373438&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.98

DO - 10.1038/clpt.2011.98

M3 - Article

C2 - 21544074

AN - SCOPUS:79959373438

VL - 90

SP - 32

EP - 39

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -